Cargando…

Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma

BACKGROUND: We sought to determine the safety and efficacy of trifluridine/tipiracil in combination with irinotecan in a phase II trial setting for refractory, advanced unresectable biliary tract carcinoma (BTC). METHODS: A total of 28 patients (27 were evaluable) with advanced BTCs who progressed o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tella, Sri Harsha, Foster, Nathan, Qian, Shi, Nguyen, Tran, Borad, Mitesh J, McWilliams, Robert R, Alberts, Steven R, Wee Ma, Wen, Chakrabarti, Sakti, Fruth, Briant, Wessling, Jaclynn, Hartgers, Mindy, Washburn, Leslie, Fernandez-Zapico, Martin E, Hogenson, Tara L, Pitot, Henry, Jin, Zhaohui, Mahipal, Amit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Clinical Trial Results
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546810/ https://www.ncbi.nlm.nih.gov/pubmed/37339254 http://dx.doi.org/10.1093/oncolo/oyad144

Ejemplares similares

Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study
por: Taniguchi, Hiroya, et al.
Publicado: (2023)

Biomarkers of Trifluridine-Tipiracil Efficacy
por: Voutsadakis, Ioannis A.
Publicado: (2021)

Trifluridine/Tipiracil: Old Drug, New Tricks
por: Jeffers, Kate D.
Publicado: (2016)

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
por: Kotani, Daisuke, et al.
Publicado: (2019)

Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study
por: Chida, Keigo, et al.
Publicado: (2021)

Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer
por: Kang, Connie, et al.
Publicado: (2019)

Correction to: Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer
por: Kang, Connie, et al.
Publicado: (2019)

Monitoring trifluridine incorporation in the peripheral blood mononuclear cells of colorectal cancer patients under trifluridine/tipiracil medication
por: Nakanishi, Ryota, et al.
Publicado: (2017)

Emerging combination therapies for metastatic colorectal cancer – impact of trifluridine/tipiracil
por: Puthiamadathil, Jeevan M, et al.
Publicado: (2017)

Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial
por: Kuboki, Yasutoshi, et al.
Publicado: (2023)

QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer
por: Tabernero, Josep, et al.
Publicado: (2017)

Extension of the European Medicines Agency (EMA) approval of trifluridine/tipiracil for gastric cancer
por: Alsina, Maria, et al.
Publicado: (2019)

Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil
por: Malik, Mateusz, et al.
Publicado: (2021)

Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil
por: Koper, Agnieszka, et al.
Publicado: (2023)

FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice
por: Kommalapati, Anuhya, et al.
Publicado: (2021)

Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells
por: Matsuoka, Kazuaki, et al.
Publicado: (2018)

Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis
por: Tabernero, Josep, et al.
Publicado: (2020)

Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study
por: García-Alfonso, Pilar, et al.
Publicado: (2021)

Trifluridine/Tipiracil in the Real-World Management of Metastatic Gastric and Gastroesophageal Junction Cancers in Canada
por: Ding, Philip Q., et al.
Publicado: (2022)

A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone
por: Cleary, James M., et al.
Publicado: (2017)

Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G)
por: Takahashi, Naoki, et al.
Publicado: (2023)

Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands
por: Kwakman, Johannes J. M., et al.
Publicado: (2017)

Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy
por: Sunakawa, Yu, et al.
Publicado: (2017)

Real‐World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib
por: Patel, Anuj K., et al.
Publicado: (2019)

Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan
por: Takushima, Yusuke, et al.
Publicado: (2021)

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
por: van de Haar, Joris, et al.
Publicado: (2023)

Evaluation of a Novel Combination Therapy, Based on Trifluridine/Tipiracil and Fruquintinib, against Colorectal Cancer
por: Nukatsuka, Mamoru, et al.
Publicado: (2023)

RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer
por: Koumarianou, Anna, et al.
Publicado: (2023)

Trifluridine/tipiracil increases survival rates in peritoneal dissemination mouse models of human colorectal and gastric cancer
por: Suzuki, Norihiko, et al.
Publicado: (2017)

Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab
por: Kamiimabeppu, Daisaku, et al.
Publicado: (2021)

Trifluridine/tipiracil increases survival rates in peritoneal dissemination mouse models of human colorectal and gastric cancer
por: Suzuki, Norihiko, et al.
Publicado: (2021)

Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis
por: Yoshino, Takayuki, et al.
Publicado: (2023)

Complete response to third-line treatment with trifluridine/tipiracil (TAS-102) in stage IV colon adenocarcinoma
por: Lara-Morga, Celia, et al.
Publicado: (2023)

Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC)
por: Kehmann, Linde, et al.
Publicado: (2023)

Trifluridine/tipiracil overcomes the resistance of human gastric 5-fluorouracil-refractory cells with high thymidylate synthase expression
por: Matsuoka, Kazuaki, et al.
Publicado: (2018)

Clinical Evaluation of the Safety and Efficacy of Trifluridine/Tipiracil in the Treatment of Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: Evidence to Date
por: Wheelden, Megan, et al.
Publicado: (2020)

Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials
por: Yoshino, T., et al.
Publicado: (2020)

Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study
por: Bachet, Jean-Baptiste, et al.
Publicado: (2020)

An Observational Study of Trifluridine/Tipiracil-Containing Regimen Versus Regorafenib-Containing Regimen in Patients With Metastatic Colorectal Cancer
por: Hsieh, Meng-Che, et al.
Publicado: (2022)

Trifluridine/tipiracil as a therapeutic option in real life setting of metastatic colorectal cancer: An efficacy and safety analysis
por: Sur, Daniel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ti2a7f77d4i78b5qhor8qsg9bm